Ellison, Gillian

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 703

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2013) · Journal of Clinical Pathology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 301

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 262

Further evidence to support the melanocytic origin of MDA-MB-435

Ellison, G. (2002) · Molecular Pathology

Cutaneous Melanoma Detection and ManagementMelanoma and MAPK Pathways

Cited by 164